Lead Sponsor

Rigel Pharmaceuticals

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of SLE or DLE (DLE confirmed histologically prior to randomization).
•At least 2 active discoid lesions secondary to SLE or DLE prior to study entry, each with a minimum Erythema Rating Score of ≥ 2. At least 1 of the active discoid lesions must have been present (by history) for ≥ 3 weeks prior to screening.
•Patients who are taking azathioprine, hydroxychloroquine, chloroquine, quinacrine, methotrexate, and/ or oral glucocorticoids, must be receiving a stable daily dose ≥ 4 weeks prior to randomization and must remain on the same dose throughout the study. Azathioprine, hydroxychloroquine, chloroquine, quinacrine, or methotrexate must be initiated ≥ 8 weeks prior to randomization.

•Congenital or acquired immunodeficiency including: HIV infection, agammaglobulinemias, T cell deficiencies or HTLV-1 infection at any time prior to the study.
•Lymphoproliferative disease or previous total lymphoid irradiation.
•Uncontrolled or poorly controlled hypertension.
•History of psoriasis, eczema, or relevant atopy.
•Exposure to excessive or chronic UV radiation (e.g., tanning beds, sunbathing, solarium, phototherapy) within 2 weeks prior to randomization or during the study period.

Related studies

NCT07330245 · Lupus Erythematosus, Systemic

NCT07015983 · Lupus Erythematosus, Systemic, Lupus Nephritis

NCT07438496 · Lupus Erythematosus, Systemic

NCT06673043 · Lupus Erythematosus, Systemic

NCT05648500 · Lupus Erythematosus, Systemic

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions